PALATIN TECHNOLOGIES, INC. Finance Lease, Principal Payments
PALATIN TECHNOLOGIES, INC. (PTN) reported Finance Lease, Principal Payments of $0 for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2026-05-13
- PALATIN TECHNOLOGIES, INC. finance lease, principal payments for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- PALATIN TECHNOLOGIES, INC. finance lease, principal payments for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- PALATIN TECHNOLOGIES, INC. finance lease, principal payments for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- PALATIN TECHNOLOGIES, INC. finance lease, principal payments for the quarter ending 2024-12-31 was $18.53K, a 29.88% decline year-over-year.
- PALATIN TECHNOLOGIES, INC. finance lease, principal payments for fiscal 2025 was $46.01K, a 56.75% decline from fiscal 2024.
- PALATIN TECHNOLOGIES, INC. finance lease, principal payments for fiscal 2024 was $106.39K, a 5.42% increase from fiscal 2023.
- PALATIN TECHNOLOGIES, INC. finance lease, principal payments for fiscal 2023 was $100.92K, a 78.74% increase from fiscal 2022.
- PALATIN TECHNOLOGIES, INC. finance lease, principal payments for fiscal 2022 was $56.46K.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 3 month as first filed | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $0.00 derived: sum of 3 quarters · filed 2026-05-13 | $18.53K derived: sum of 4 quarters · filed 2026-05-13 | |
| 2025-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $0.00 derived: sum of 2 quarters · filed 2026-05-13 | $18.53K derived: sum of 3 quarters · filed 2026-05-13 | $46.01K 10-K · filed 2025-09-23 | |
| 2025-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13 | $18.53K derived: sum of 2 quarters · filed 2026-05-13 | $46.01K 10-Q · filed 2026-05-13 | $73.14K derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $18.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | $46.01K 10-Q · filed 2026-02-17 | $73.14K derived: sum of 3 quarters · filed 2026-02-17 | $99.91K derived: sum of 4 quarters · filed 2026-02-17 | |
| 2024-09-30 | $27.49K 10-Q · filed 2025-11-14 | $54.61K derived: sum of 2 quarters · filed 2025-11-14 | $81.39K derived: sum of 3 quarters · filed 2025-11-14 | $107.81K derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $27.13K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $53.90K derived: sum of 2 quarters · filed 2025-09-23 | $80.32K derived: sum of 3 quarters · filed 2025-09-23 | $106.39K 10-K · filed 2025-09-23 | |
| 2024-03-31 | $26.77K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-14 | $53.19K derived: sum of 2 quarters · filed 2025-05-14 | $79.27K 10-Q · filed 2025-05-14 | $105.00K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $26.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-13 | $52.49K 10-Q · filed 2025-02-13 | $78.23K derived: sum of 3 quarters · filed 2025-02-13 | $103.62K derived: sum of 4 quarters · filed 2025-02-13 | |
| 2023-09-30 | $26.07K 10-Q · filed 2024-11-14 | $51.81K derived: sum of 2 quarters · filed 2024-11-14 | $77.20K derived: sum of 3 quarters · filed 2024-11-14 | $127.00K derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $25.73K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | $51.13K derived: sum of 2 quarters · filed 2024-09-30 | $100.92K derived: sum of 3 quarters · filed 2024-09-30 | $100.92K 10-K · filed 2024-09-30 | |
| 2023-03-31 | $25.39K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $75.19K derived: sum of 2 quarters · filed 2024-05-15 | $75.19K 10-Q · filed 2024-05-15 | $99.60K derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $49.79K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | $49.79K 10-Q · filed 2024-02-14 | $74.21K derived: sum of 3 quarters · filed 2024-02-14 | $98.30K derived: sum of 4 quarters · filed 2024-02-14 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-14 | $24.73K 10-Q · filed 2022-11-14 | $24.41K derived: sum of 2 quarters · filed 2023-11-14 | $48.50K derived: sum of 3 quarters · filed 2023-11-14 | $56.46K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $24.41K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-22 | $48.50K derived: sum of 2 quarters · filed 2023-05-15 | $56.46K derived: sum of 3 quarters · filed 2023-05-15 | $56.46K 10-K · filed 2022-09-22 | |
| 2022-03-31 | $24.09K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | $32.05K derived: sum of 2 quarters · filed 2023-05-15 | $32.05K 10-Q · filed 2023-05-15 | $32.05K derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | $7.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-14 | $7.96K 10-Q · filed 2023-02-14 | $7.96K derived: sum of 3 quarters · filed 2023-02-14 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | |||
| 2021-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-22 | $0.00 10-K · filed 2022-09-22 | |||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |